Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia [4]

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1319-1320

  Dizdar, Ömer ^a   Yürekli, Banu Şarer ^a   Pürnak, Tugrul ^a   Aksu, Salih ^a   Haznedaroǧlu, Ibrahim Celalettin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM; CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; CREATININE; FLUDARABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; NITROGEN; POTASSIUM; UREA; URIC ACID;

AGED; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FLOW CYTOMETRY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; TUMOR LYSIS SYNDROME; VIDARABINE;

EID: 3042694220     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D538     Document Type: Letter

References (5)

1. Jeha S. Tumor lysis syndrome. Semin Hematol 2001;38(suppl 10):4-8.
2. Frame JN, Dahut WL, Crowley S. Fludarabine and acute tumor lysis in chronic lymphocytic leukemia (letter). N Engl J Med 1992;327:1396-7.
3. Nakhoul F, Green J, Abbasi ZA, Carter A. Tumor lysis syndrome induced by fludarabine monophosphate: a case report. Eur J Haematol 1996;56:254-5.
4. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313-20.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.